IMOP: Randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - Clinical trial with analyses of efficacy, cost effectiveness and acceptability

BMC Pregnancy and Childbirth

Volumn 6, Issue , 2006, Pages

  Bollapragada, Shrikant ^a   Mackenzie, Fiona ^b   Norrie, John ^c   Petrou, Stravros ^d   Reid, Margaret ^e   Greer, Ian ^a   Osman, Inass ^a   Norman, Jane E ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Aberdeen University ^*  (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE MONONITRATE; PLACEBO;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; LABOR INDUCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX RIPENING; VAGINAL DELIVERY;

EID: 33748881378     PISSN: 14712393     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-6-25     Document Type: Article

References (38)

1. Royal College of Obstetricians and Gynaecologists: Induction of labour RCOG: London; 2001.
2. Stitely ML, Browning J, Fowler M, Gendron RT, Gherman RB: Outpatient cervical ripening with intravaginal misoprostol. Obstet Gynecol 2000, 96(5 Pt 1):684-8.
3. McKenna DS, Costa SW, Samuels P: Prostaglandin E2 cervical ripening without subsequent induction of labor. Obstet Gynecol 1999, 94(1):11-4.
4. Farmer KC, Schwartz WJ 3rd, Rayburn WF, Turnbull G: A cost-minimization analysis of intracervical prostaglandin E2 for cervical ripening in an outpatient versus inpatient setting. Clin Ther 1996, 18(4):747-56. discussion 702
5. Biem SR, Turnell RW, Olatunbosun O, Tauh M, Biem HJ: A randomized controlled trial of outpatient versus inpatient labour induction with vaginal controlled-release prostaglandin-E2: effectiveness and satisfaction. J Obstet Gynaecol Can 2003, 25(1):23-31.
6. Rayburn W, Tassone S, Pearman C: Is cervidil appropriate for outpatient cervical ripening. Obstet Gynecol 2000, 95:S63.
7. Voss DH, Cumminsky KC, Cook VD, Nethers MS, Spinnato JA, Gall SA: Effect of three concentrations of intracervical prostaglandin E2 gel for cervical ripening. J Matern Fetal Med 1996, 5(4):186-93.
8. Thomson A, Lunan C, Cameron A, Cameron I, Greer I, Norman J: Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. British Journal of Obstetrics and Gynaecology 1997, 104:1054-1057.
9. Thomson AJ, Lunan CB, Ledingham M, Howat RC, Cameron IT, Greer IA, Norman JE: Randomised trial of nitric oxide donor versus prostaglandin for cervical ripening before first-trimester termination of pregnancy. Lancet 1998, 352(9134):1093-6.
10. Nicoll A, Mackenzie F, Greer I, Norman J: Vaginal application of the nitric oxide donor isosorbide mononitrate for pre-induction cervical ripening: a randomised controlled trial to determine effects on maternal and fetal haemodynamics. American Journal of Obstetrics and Gynecology 2001, 184:958-964.
11. Osman I, MacKenzie F, Norrie J, Murray HM, Greer IA, Norman JE: The "PRIM" study: a randomized comparison of prostaglandin E2 gel with the nitric oxide donor isosorbide mononitrate for cervical ripening before the induction of labor at term. Am J Obstet Gynecol 2006, 194(4):1012-21.
12. Ekerhovd E, Bullarbo M, Andersch B, Norstrom A: Vaginal administration of the nitric oxide donor isosorbide mononitrate for cervical ripening at term: a randomized controlled study. Am J Obstet Gynecol 2003, 189(6):1692-7.
13. Tassone SA, Pearman CR, Rayburn WF: Outpatient cervical ripening using a sustained-release prostaglandin E2 vaginal insert. J Reprod Med 2001, 46(6):599-600.
14. Sanchez-Ramos L, Kaunitz AM: Outpatient cervical ripening with intravaginal misoprostol. Obstet Gynecol 2001, 97(2):325-6.
15. Rayburn W, Lucas M, Gittens L, Goodwin TM, Baxi L, Gall S, Mostello D, Heyl P: Attempted vaginal birth after cesarean section: a multicenter comparison of outpatient prostaglandin E(2) gel with expectant management. Prim Care Update Ob Gyns 1998, 5(4):182-183.
16. Rayburn W, Gosen R, Ramadei C, Woods R, Scott J Jr: Outpatient cervical ripening with prostaglandin E2 gel in uncomplicated postdate pregnancies. Am J Obstet Gynecol 1988, 158(6 Pt 1):1417-23.
17. Neale E, Pachulski A, Whiterod S, McGuinness E, Gallagher N, Wallace R: Outpatient cervical ripening prior to induction of labour. J Obstet Gynaecol 2002, 22(6):634-5.
18. Larmon JE, Magann EF, Dickerson GA, Morrison JC: Outpatient cervical ripening with prostaglandin E2 and estradiol. J Matern Fetal Neonatal Med 2002, 11(2):113-7.
19. Incerpi MH, Fassett MJ, Kjos SL, Tran SH, Wing DA: Vaginally administered misoprostol for outpatient cervical ripening in pregnancies complicated by diabetes mellitus. Am J Obstet Gynecol 2001, 185(4):916-9.
20. Evans MI, Dougan MB, Moawad AH, Evans WJ, Bryant-Greenwood GD, Greenwood FC: Ripening of the human cervix with porcine ovarian relaxin. Am J Obstet Gynecol 1983, 147(4):410-4.
21. Elliott JP, Clewell WH, Radin TG: Intracervical prostaglandin E2 gel. Safety for outpatient cervical ripening before induction of labor. J Reprod Med 1992, 37(8):713-6.
22. Sawai SK, O'Brien WF, Mastrogiannis DS, Krammer J, Mastry MG, Porter GW: Patient-administered outpatient intravaginal prostaglandin E2 suppositories in post-date pregnancies: a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1994, 84(5):807-10.
23. Sawai SK, Williams MC, O'Brien WF, Angel JL, Mastrogiannis DS, Johnson L: Sequential outpatient application of intravaginal prostaglandin E2 gel in the management of postdates pregnancies. Obstet Gynecol 1991, 78(1):19-23.
24. Sciscione AC, Muench M, Pollock M, Jenkins TM, Tildon-Burton J, Colmorgen GH: Transcervical Foley catheter for preinduction cervical ripening in an outpatient versus inpatient setting. Obstet Gynecol 2001, 98(5 Pt 1):751-6.
25. Smith MA, Swan L, Caruthers BS, Heaton C: Outpatient use of prostaglandin gel for ripening of the cervix and induction of labor. J Fam Pract 1990, 30(6):656-62. discussion 662-4
26. Upadhyaya NB, Childs KD, Neiger R, Caudle MR: Ambulatory cervical ripening in term pregnancy. J Reprod Med 1999, 44(4):363-6.
27. Chanrachakul B, Herabutya Y, Punyavachira P: Randomised comparison of glyceryl trinitrate and prostglandin E2 for cervical ripening at term. Obstetrics and Gynecology 2000, 96:549-553.
28. Chanrachakul B, Herabutya Y, Punyavachira P: Randomized trial of isosorbide mononitrate versus misoprostol for cervical ripening at term. Int J Gynaecol Obstet 2002, 78(2):139-45.
29. Hofmeyr GJ, Gulmezoglu AM: Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2003:CD000941.
30. Schaff EA, Stadalius LS, Eisinger SH, Franks P: Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997, 44(4):353-60.
31. Bates CD, Nicoll AE, Mullen AB, Mackenzie F, Thomson AJ, Norman JE: Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. Bjog 2003, 110(1):64-7.
32. Roberts TE: Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. The Extracorporeal Membrane Oxygenation Economics Working Group. Bmj 1998, 317(7163):911-5. discussion 915-6
33. Barbour R: Are focus groups an appropriate tool for studying organisational change. In Developing focus group research Edited by: Barbour R, Kitzinger J. Sage: London; 1999.
34. Drummond MF, O'Brien B, Stoddart G, Torrance G: Methods for the economic evaluation of health care programmes 2nd edition. Oxford: OUP; 1999.
35. Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ 1996, 5(4):297-305.
36. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Bmj 1998, 317(7160):720-6.
37. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976, 34(6):585-612.
38. Centre for Health Care and Randomised Trials: IMOP study [https://www.charttrials.abdn.ac.uk/imop/studysite/index.php].